Cyanuric acid

Particle size distribution (Granulometry)

Link to relevant study record(s)

Reference

Endpoint:

particle size distribution (granulometry)

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 110 (Particle Size Distribution / Fibre Length and Diameter Distributions)

GLP compliance:

yes

Type of method:

sieving

Type of distribution:

counted distribution

No.:

#1

Size:

< 100 µm

Distribution:

ca. 38 %

No.:

#2

Size:

< 10 µm

Distribution:

ca. 0.734 %

No.:

#3

Size:

< 5.5 µm

Distribution:

ca. 0.356 %

Table 1: Results of sieving procedure

Sieve aperture size (µm)	100
Mass of test material transferred to sieve (g)	10.58
Mass of test material passed through sieve (g)	4.09
Test material less than sieve aperture size (%)	38.7

Table 2: Overall cumulative amounts of cyanuric acid with a particle size < 10 µm (%) from determinations 1 to 3:

Determination	Cumulative amount of test material < 10.0 µm (%)	Mean cumulative amount of test material < 10.0 µm (%)
1	1.22	0.734
2	0.665
3	0.317

 

Table 3: Overall cumulative amounts of cyanuric acid with a particle size < 5.5 µm (%) from determinations 1 to 3

Determination	Cumulative amount of test material < 5.5 µm (%)	Mean cumulative amount of test material < 5.5 µm (%)
1	0.461	0.356
2	0.439
3	0.169

 

Too few particles were of a size less than 10.0 µm to allow accurate assessment of mass median aerodynamic diameter. Representative sampling was ensured by rolling the sample container for approximately 10 minutes and sampling from the top, middle and bottom prior to definitive testing. The inhalable fraction is defined as the mass fraction of particles which can be inhaled by nose or mouth, the thoracic fraction is defined as the mass fraction of particles that passes the larnyx and the respirable fraction is defined as the mass fraction of particles that reaches the alveoli.

Conclusions:

Proportion of CYA having an inhalable particle size < 100 µm (sieve method) = 38.7%
Proportion of CYA having a thoracic particle size < 10.0µm (cascade impactor method) = 0.734%
Proportion of CYA having a respirable particle size < 5.5 µm (cascade impactor method) = 0.356%

Description of key information

Particle size distribution was performed according to OECD guideline 110

Additional information

Proportion of CYA having an inhalable particle size < 100 µm (sieve method) = 38.7%

Proportion of CYA having a thoracic particle size < 10.0µm (cascade impactor method) = 0.734%

Proportion of CYA having a respirable particle size < 5.5 µm (cascade impactor method) = 0.356%